UBS Group’s Rocket Pharmaceuticals Warrant RCKTW Stock Holding History

UBS Group’s Portfolio RCKTW Stock Details RCKTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$84	Buy	+3,981	New	+$80	﹤0.01%	10142
2025 Q4	–	Sell	-1,274	Closed	-$50	–	11058
2025 Q3	$50	Buy	+1,274	New	+$50	﹤0.01%	10023
2024 Q3	–	Sell	-24	Closed	-$1	–	9971
2024 Q2	$1	Sell	24 -75	-76%	-$9	﹤0.01%	9434
2024 Q1	$30	Buy	+99	New	+$31	﹤0.01%	8991

Other funds holding RCKTW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

UBS Group's RCKTW Position: Q1 2026 in Review

UBS Group opened a new position in Rocket Pharmaceuticals Warrant (RCKTW) in Q1 2026: 3,981 shares worth $84. The stake represents ﹤0.01% of the portfolio and ranks #10142 among its holdings. This is a return to the name: UBS Group previously reported a position in RCKTW as recently as Q3 2025.

UBS Group first reported a position in RCKTW in Q1 2024 and has held it in 4 quarters since. 10 funds tracked by Wall St. Rank hold RCKTW as of Q1 2026.

UBS Group held 3,981 shares of Rocket Pharmaceuticals Warrant worth $84 as of Q1 2026.
Rocket Pharmaceuticals Warrant was a new UBS Group position in Q1 2026.
Rocket Pharmaceuticals Warrant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10142 holding.
UBS Group first reported a position in Rocket Pharmaceuticals Warrant in Q1 2024 and has held it in 4 quarters since.
10 funds tracked by Wall St. Rank held Rocket Pharmaceuticals Warrant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.